Information Provided By:
Fly News Breaks for February 10, 2016
REGN
Feb 10, 2016 | 07:18 EDT
Brean Capital lowered its price target on Regeneron to $489 from $659 following Q4 results. The firm cited lower Eylea growth, which was in-line with expectations. The firm sees many other potential revenue drivers and lowered its price target to reflect adjustments to its model. Brean Capital reiterated its Buy rating on Regeneron shares.